adagrasib
mirati
['adagrasib']
in the registration phase 2 cohort of 116 patients with krasg12c mutations who were treated with adagrasib median duration of response was 8.5 months, median pfs 6.5m and median os was 12.6m. #asco2022
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"